Evidence map›Paper›PMID 21229291›Full record

ArticleJournal of neuro-oncology2011

Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas.

Ganeshkumar Rajendran, Karthik Shanmuganandam, Ameya Bendre, Dattatraya Muzumdar, Dattatreya Mujumdar, Abhay Goel, Anjali Shiras

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 124 citations in OpenAlex.

  1. Methylome of fetal and maternal monocytes and macrophages at the feto-maternal interface.American journal of reproductive immunology (New York, N.Y. : 1989) · 2012
    Trial
  2. Article
  3. Article
  4. Fumonisin BEpigenetics · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Role of DNMTs in the Brain.Advances in experimental medicine and biology · 2022
    Review
  18. Review
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Mujumdar, Dattatreya [corrected to Muzumdar, Dattatraya]
5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ganeshkumar RajendranNational Centre for Cell Science (NCCS), Pune, India.
Karthik Shanmuganandam
Ameya Bendre
Dattatraya Muzumdar
Dattatreya Mujumdar
Abhay Goel
Anjali Shiras
National Centre for Cell Science · INKing Edward Memorial Hospital and Seth G.S. Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of epigenetics and significance of aberrant gene regulation in etiology of cancer is a well-established phenomenon. The hallmark of cancer epigenetics is aberrant DNA methylation consisting of global hypomethylation and regional hypermethylation of tumor suppressor genes (TSGs) by DNA methyltransferases (DNMTs). In mammals, DNA methylation is catalyzed by DNMTs encoded by DNMT1, DNMT3A, and DNMT3B. Interestingly, little is known about variation in the methylation status of epigenetic regulators themselves in gliomas. Here, we report significant overexpression of DNMT1 and DNMT3B. A study of the methylation status and histone modifications at the promoter region of DNA methyltransferase I (DNMT1) gene revealed an unmethylated DNA promoter, similar to that detected in normal brain tissues. However, a differential histone code with distinct euchromatin marks--AcH3, AcH4, and H3k4me2--was specifically detected in tumors, unlike in normal brain tissues, which were found predominantly enriched with heterochromatin marks such as H3K9me2 and H3K27me3. In contrast, a differential methylation pattern of DNMT3B gene promoter occurred in glioma tumors, wherein it was found hypomethylated. Transcriptional silencing by CpG island methylation is a prevalent mechanism for inactivation of TSGs. Inhibiting DNMTs by 5-azacytidine (DNMT inhibitor) treatment led to significant inhibition of expression of DNMT1 and DNMT3B and enhanced expression of TSGs such as PTEN and p21 analyzed in this study. Our studies have identified effects of increased presence of DNMTs on inhibition of tumor suppressors that are epigenetically silenced in gliomas, thereby leading to aberrant regulation of cell cycle progression and failure to maintain genomic stability.

Indexed as

Epigenesis, GeneticAdolescentAdultAgedBrain NeoplasmsChildDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3BFemaleGliomaHumansMaleMiddle AgedOligonucleotide Array Sequence AnalysisDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3BDNMT1 protein, human

Identifiers

PMID21229291
OpenAlexW2064871082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.